{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+Comparator%3A+A&page=28",
    "query": {
      "intervention": "Active Comparator: A",
      "page": 28
    },
    "page_size": 10
  },
  "pagination": {
    "page": 28,
    "page_size": 10,
    "total_count": 1583,
    "total_pages": 159,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+Comparator%3A+A&page=29&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+Comparator%3A+A&page=27&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T09:10:43.243Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02371746",
      "title": "Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glaucoma and Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "ENV515-3 Travoprost XR",
          "type": "DRUG"
        },
        {
          "name": "ENV515-1 Travoprost XR",
          "type": "DRUG"
        },
        {
          "name": "ENV515-3-2 Travoprost XR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Envisia Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 41,
      "start_date": "2015-01-01",
      "completion_date": "2019-02-13",
      "has_results": true,
      "last_update_posted_date": "2019-10-17",
      "last_synced_at": "2026-11-19T09:10:43.243Z",
      "location_count": 14,
      "location_summary": "Chandler, Arizona • Garden Grove, California • Inglewood, California + 11 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Redding",
          "state": "California"
        },
        {
          "city": "Morrow",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02371746"
    },
    {
      "nct_id": "NCT04378569",
      "title": "Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Hand Eczema"
      ],
      "interventions": [
        {
          "name": "ARQ-252 cream 0.3%",
          "type": "DRUG"
        },
        {
          "name": "ARQ-252 cream 0.1%",
          "type": "DRUG"
        },
        {
          "name": "ARQ-252 Vehicle Cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arcutis Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 230,
      "start_date": "2020-04-20",
      "completion_date": "2021-02-24",
      "has_results": true,
      "last_update_posted_date": "2024-04-05",
      "last_synced_at": "2026-11-19T09:10:43.243Z",
      "location_count": 25,
      "location_summary": "Beverly Hills, California • Encino, California • Fremont, California + 21 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04378569"
    },
    {
      "nct_id": "NCT07105007",
      "title": "Proof-of-concept of a Behavioral Intervention to Improve the Cardiovascular Health of People Living With HIV",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV",
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "Exercise Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Tailored Education sessions",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Behavioral coaching",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Mobile health support",
          "type": "BEHAVIORAL"
        },
        {
          "name": "General education",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2025-08-15",
      "completion_date": "2026-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-16",
      "last_synced_at": "2026-11-19T09:10:43.243Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07105007"
    },
    {
      "nct_id": "NCT07812987",
      "title": "Rapid Entrainment and Signal-guided Neuromodulation for Behavioral Health",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Anxiety",
        "PTSD",
        "ADHD",
        "Depression Disorders",
        "Post-traumatic Stress",
        "Substance Use",
        "Executive Function",
        "Sleep Disturbance"
      ],
      "interventions": [
        {
          "name": "AIP-Informed Integrative Psychotherapy",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Transcutaneous Auricular Vagus Nerve Stimulation",
          "type": "DEVICE"
        },
        {
          "name": "Regulated Breathing and Autonomic Regulation",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Audiovisual Entrainment",
          "type": "DEVICE"
        },
        {
          "name": "Vibroacoustic Stimulation",
          "type": "DEVICE"
        },
        {
          "name": "Breathwork-Based Auditory Driving Entropy Module (BADEM)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Transcranial Electrical Stimulation",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DEVICE"
      ],
      "sponsor": "Tactical Mind Research Coalition, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 240,
      "start_date": "2026-08-01",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-16",
      "last_synced_at": "2026-11-19T09:10:43.243Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07812987"
    },
    {
      "nct_id": "NCT03945292",
      "title": "Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alpha 1-Antitrypsin Deficiency"
      ],
      "interventions": [
        {
          "name": "Fazisiran Injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Arrowhead Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 40,
      "start_date": "2019-08-07",
      "completion_date": "2023-09-18",
      "has_results": true,
      "last_update_posted_date": "2025-11-04",
      "last_synced_at": "2026-11-19T09:10:43.243Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03945292"
    },
    {
      "nct_id": "NCT01669980",
      "title": "Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Infections",
        "Pneumonia"
      ],
      "interventions": [
        {
          "name": "Ceftaroline fosamil",
          "type": "DRUG"
        },
        {
          "name": "IV Ceftriaxone and Vancomycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Forest Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Months to 18 Years"
      },
      "enrollment_count": 40,
      "start_date": "2012-10",
      "completion_date": "2014-08",
      "has_results": false,
      "last_update_posted_date": "2015-11-02",
      "last_synced_at": "2026-11-19T09:10:43.243Z",
      "location_count": 13,
      "location_summary": "Long Beach, California • Oakland, California • Orange County, California + 10 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Orange County",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01669980"
    },
    {
      "nct_id": "NCT00143520",
      "title": "Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Rivoglitazone",
          "type": "DRUG"
        },
        {
          "name": "Pioglitazone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 441,
      "start_date": "2004-12",
      "completion_date": "2005-12",
      "has_results": false,
      "last_update_posted_date": "2021-05-10",
      "last_synced_at": "2026-11-19T09:10:43.243Z",
      "location_count": 74,
      "location_summary": "Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 71 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Columbiana",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00143520"
    },
    {
      "nct_id": "NCT04446117",
      "title": "Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Prostate Cancer",
        "Prostate Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone Acetate",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Exelixis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 575,
      "start_date": "2020-10-19",
      "completion_date": "2026-10-16",
      "has_results": true,
      "last_update_posted_date": "2025-12-18",
      "last_synced_at": "2026-11-19T09:10:43.243Z",
      "location_count": 36,
      "location_summary": "Tucson, Arizona • Duarte, California • Fullerton, California + 30 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Marina del Rey",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04446117"
    },
    {
      "nct_id": "NCT05743335",
      "title": "A Phase 1 Study to Assess the Safety and Immunogenicity of JCXH-221, an MRNA-based Broadly Protective COVID-19 Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID-19",
        "Infectious Disease"
      ],
      "interventions": [
        {
          "name": "JCXH-221",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Immorna Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 73,
      "start_date": "2023-03-07",
      "completion_date": "2023-12-01",
      "has_results": false,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-11-19T09:10:43.243Z",
      "location_count": 4,
      "location_summary": "Hallandale, Florida • Savannah, Georgia • Lincoln, Nebraska + 1 more",
      "locations": [
        {
          "city": "Hallandale",
          "state": "Florida"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        },
        {
          "city": "Cedar Park",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05743335"
    },
    {
      "nct_id": "NCT03443076",
      "title": "Bioavailability of EPA + DHA in a SMEDS Formulation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Bioavailability"
      ],
      "interventions": [
        {
          "name": "EPA + DHA in SMEDS Formulation",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Lovaza (active comparator; already FDA approved)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Midwest Center for Metabolic and Cardiovascular Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2018-02-16",
      "completion_date": "2018-04-15",
      "has_results": false,
      "last_update_posted_date": "2023-03-23",
      "last_synced_at": "2026-11-19T09:10:43.243Z",
      "location_count": 2,
      "location_summary": "Boca Raton, Florida • Chicago, Illinois",
      "locations": [
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03443076"
    }
  ]
}